Drug intelligence / Profile preview

ATI-2231

Development stage: Discontinued
Lead developer: Aclaris Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ATI-2231 is an orally bioavailable small molecule inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2), developed by Aclaris Therapeutics. It was designed to have a long half-life and was investigated for its potential antineoplastic effects, particularly in advanced solid tumors, metastatic breast cancer, pancreatic cancer, and bone disorders. By inhibiting MK2, ATI-2231 aimed to slow or stop tumor cell growth and potentially improve symptoms related to inflammation and bone loss. Clinical development has been discontinued in favor of a more advanced compound from the same class[1][2][3][5][6][8].

Targets

MK2 (Mitogen-activated protein kinase-activated protein kinase 2)

Beyond the preview

Go deeper on ATI-2231.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATI-2231.

Explore the full profile